ChromaDex, Inc. Vindicated By Retraction And Apology From Author Of Misleading And Factually Inaccurate Article

IRVINE, Calif., June 30, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), a leading provider of proprietary science-backed technologies and analytical services for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that an article by Bleecker Street Research published on Seeking Alpha on June 20, 2016 has been removed and replaced with an apology from the author.

The following message has replaced the article:

“This article has been removed from the site. The below is a message from the author.

Bleecker Street Research is removing its article on Barry Honig, ChromaDex, and Pershing Gold. After further research we believe that the statements were not supported and the premise of the article was allegedly factually inaccurate. Bleecker Street would like to apologize to ChromaDex, Pershing Gold, and Barry Honig for an allegedly misleading article and to immediately set the record straight for our readers who should not rely on certain aspects upon the withdrawn article or statements of the author therein. To our readers: In the future we will document everything even more carefully.”

ChromaDex published a press release on June 20, 2016 refuting the allegations. Additionally, Frank Jaksch Jr., Founder and CEO of ChromaDex, published a shareholder letter on June 24, 2016 debunking the multiple false allegations, which can be found on the investor relations section of

About ChromaDex:
ChromaDex, a leading provider of science-backed technologies and analytical services, connects the knowledge and key relationships within its complementary businesses to discover, acquire, develop, and commercialize patented and proprietary health related innovations. The company utilizes their in-house chemistry, regulatory and safety consulting expertise (Spherix Consulting) to develop revolutionary ingredients such as NIAGEN®, the only commercially available form of nature-identical nicotinamide riboside; pTeroPure® pterostilbene; PURENERGY®, a caffeine-pTeroPure® co-crystal; IMMULINA, a spirulina extract; and anthocyanins derived from a domestically-produced, water-extracted, non-GMO, purple corn hybrid. ChromaDex technologies drive advancements in health and wellness for the dietary supplement, sports nutrition, pharmaceutical, food and beverage and skin care industries. To learn more about ChromaDex, please visit

Forward-Looking Statements:
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in ChromaDex's business. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex's Annual Report on Form 10-K for the fiscal year ended January 2, 2016, ChromaDex's Quarter Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC's website at Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

ChromaDex Investor Contact: Andrew Johnson, Director of Investor Relations 949-419-0288

Primary Logo

Back to news